Famke C Wakkerman, Jiqing Wu, Hein Putter, Ina M Jürgenliemk-Schulz, Jan J Jobsen, Ludy C H W Lutgens, Marie A D Haverkort, Marianne A de Jong, Jan Willem M Mens, Bastiaan G Wortman, Remi A Nout, Alicia Léon-Castillo, Melanie E Powell, Linda R Mileshkin , Dionyssios Katsaros, Joanne Alfieri, Alexandra Leary, Naveena Singh, Stephanie M de Boer, Hans W Nijman, Vincent T H B M Smit, Tjalling Bosse, Viktor H Koelzer, Carien L Creutzberg, Nanda Horeweg

Lancet Oncol. 2024 Jun;25(6):779-789.

doi: 10.1016/S1470-2045(24)00142-6. Epub 2024 Apr 30.

Abstract

Background: Numerous studies have shown that older women with endometrial cancer have a higher risk of recurrence and cancer-related death. However, it remains unclear whether older age is a causal prognostic factor, or whether other risk factors become increasingly common with age. We aimed to address this question with a unique multimethod study design using state-of-the-art statistical and causal inference techniques on datasets of three large, randomised trials.

Methods: In this multimethod analysis, data from 1801 women participating in the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trials were used for statistical analyses and causal inference. The cohort included 714 patients with intermediate-risk endometrial cancer, 427 patients with high-intermediate risk endometrial cancer, and 660 patients with high-risk endometrial cancer. Associations of age with clinicopathological and molecular features were analysed using non-parametric tests. Multivariable competing risk analyses were performed to determine the independent prognostic value of age. To analyse age as a causal prognostic variable, a deep learning causal inference model called AutoCI was used.

Findings: Median follow-up as estimated using the reversed Kaplan-Meier method was 12·3 years (95% CI 11·9-12·6) for PORTEC-1, 10·5 years (10·2-10·7) for PORTEC-2, and 6·1 years (5·9-6·3) for PORTEC-3. Both overall recurrence and endometrial cancer-specific death significantly increased with age. Moreover, older women had a higher frequency of deep myometrial invasion, serous tumour histology, and p53-abnormal tumours. Age was an independent risk factor for both overall recurrence (hazard ratio [HR] 1·02 per year, 95% CI 1·01-1·04; p=0·0012) and endometrial cancer-specific death (HR 1·03 per year, 1·01-1·05; p=0·0012) and was identified as a significant causal variable.

Interpretation: This study showed that advanced age was associated with more aggressive tumour features in women with endometrial cancer, and was independently and causally related to worse oncological outcomes. Therefore, our findings suggest that older women with endometrial cancer should not be excluded from diagnostic assessments, molecular testing, and adjuvant therapy based on their age alone.